Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine

This study was aimed to conduct a 3-year perspective study to observe the immunological effect of one-dose mumps-containing vaccine, monitor the incidence of mumps in vaccinated population aged 3-7 years，and provide basis for adjusting MMR immunization strategy in Jiangsu province, China.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parotid Gland Infection Body Temperature Changes Fever Infections Mononegavirales Infections Mouth Diseases Mumps Paramyxoviridae Infections Parotid Diseases Parotitis Pathological Conditions, Signs and Symptoms RNA Virus Infections Rubulavirus Infections Salivary Gland Diseases Signs and Symptoms Stomatognathic Diseases Virus Diseases

Age range

3 year–7 year

Sex eligibility

All sexes

Study type

Observational

Primary location

wujin district CDC, Changzhou, Jiangsu, China

About this study

in 3-7 years old children with high risk of mumps, epidemiological investigation of the serum IgG antibody level were conducted, and then a prospective observational cohort was established in the population with a history of mumps vaccination, and the incidence of mumps in each antibody level group will be observed, the relationship between different antibody levels and the incidence after mumps vaccinated were analyzed, to explore attenuation of mumps IgG antibody levels in the body,S79 vaccine strain against F genotype mumps' antigenic cross-reactivity and the protective effect of antibodies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children aged 3-7 years old;
local resident children living at least 3 months;
physical health, has been vaccinated at least once a dose of MuV

Exclusion criteria

did not administer MuV;
refused to collect venous blood;
have been infected with mumps;
have serious illness or other reasons should not participate in the study after clinical evaluation

Treatment and study plan

Primary outcomes

to describe the sero-prevalence in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years

Secondary outcomes

to describe wane immunity of IgG antibody to mumps virus in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years
To characterize the incidence of mumps in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Jiangsu Province Centers for Disease Control and Prevention

Network

Registry information

Official study title

Observational Cohort Study to Evaluate Immunogenicity, Protection, and Persistence of Antibody to Mumps in 3-7 Years' Children Received One-dose Mumps-containing Vaccine

Important dates

Study start: 2015
Primary completion: 2017
Study completion: 2017
First posted: Sep 15, 2016
Registry last updated: Jun 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed